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ScienceDirectThe biology and regulation of YAP and TAZ, two closely related
transcriptional regulators, are receiving increasing attention
owing to their fundamental roles in organ growth, tissue repair
and cancer. In particular, the widespread activation of YAP/
TAZ in carcinomas, and the crucial role of YAP/TAZ activation
for many ‘hallmarks’ of cancer are indicating YAP/TAZ as prime
targets for designing anti-cancer drugs. Here, we start from the
known modalities to regulate YAP/TAZ to highlight possible
routes of therapeutic intervention.
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The current surge of interest on YAP/TAZ biology and
regulation is fueled by the realization that YAP/TAZ are
pervasively activated in human tumors [1,2] and by some
striking genetic evidence in mouse models, collectively
indicating that inactivation of YAP/TAZ in several adult
organs — including breast, liver, pancreas, skin and in-
testine [3,4,5,6,7] — renders those tissues immune to
cancer emergence or progression. Notably, YAP/TAZ
inactivation has no overt adverse effects on the basal
homeostasis of the surrounding healthy tissue. The cel-
lular and molecular bases of these phenomena remain
poorly understood.
A conceptually unifying notion that integrates the several
roles of YAP/TAZ in cancer is their unique ability to
install cancer-stem cell (CSC) properties in otherwise
benign tumor cells [8,9]. Moreover, YAP/TAZ are re-
quired to preserve stemness properties in established
CSC populations. It has been proposed that tumors
progress by increasing their CSC content; YAP/TAZCurrent Opinion in Pharmacology 2016, 29:26–33 appear to contribute to this phenomenon by generating
new CSCs.
The connection between YAP/TAZ and stemness entails
the ability of YAP/TAZ to promote self-renewal and the
capacity to proliferate in spite of growth-suppressive envi-
ronmental conditions. It is worth noting that some of these
attributes are not specific to CSCs, as they are also associ-
ated to normal somatic SCs; consistently, YAP/TAZ are
also essential for physiological tissue repair upon injury
[7,10]. This suggests the tempting possibility that carcino-
mas may have actually hijacked one ancestral property of
YAP/TAZ — that is, endowing stemness to build and
repair organs in order to induce recurrence and metastasis.
Whereas somatic SCs require specific signals from local-
ized tissue niches in order to activate YAP/TAZ, these
signals may be abundant and widespread within the tumor
microenvironment or bypassed by cancer-specific muta-
tions. For these reasons, major emphasis in YAP/TAZ
research has been placed on the mechanisms of their
regulation.
Although the field remains riddled with many open
questions, the available evidence is nevertheless suffi-
cient to pinpoint YAP/TAZ as prime candidates for the
development of effective cancer treatments. Here we will
review some of the most promising research avenues and
proofs-of-concept toward these goals.
YAP/TAZ regulation by the Hippo cascade
The function of YAP/TAZ has been classically understood
in the context of Hippo signaling, whose core components
are the evolutionary conserved kinases LAST1/2 and
MST1/2 (related to Drosophila Hippo kinase) and their
associated co-factors SAV1 and MOB1/2 [2,11]. When the
pathway is turned ON, YAP/TAZ are OFF, as LATS1/2
phosphorylate and negatively regulate YAP/TAZ restrict-
ing their stability or nuclear localization. The Hippo cas-
cade represents a key limiting factor for YAP/TAZ, as
experimental inactivation of Hippo kinase activity during
embryonic development results in aberrantly oversized
organs or defective differentiation (reviewed in [2,11]).
That said, Hippo pathway mutations are virtually absent
in human carcinomas, rendering this cascade an unlikely
candidate to explain the wide and robust activation of
YAP/TAZ in most, if not all solid tumors [1,2]. Of note,
loss-of-function mutations in LATS 1/2 or in NF2 (an
upstream Hippo pathway component acting as MST
positive regulator) are actually selected in specific tumors,www.sciencedirect.com
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[1]. Any therapeutic intervention aimed at restoring the
Hippo pathway in these tumors is challenging, as it would
entail the design of compounds aiming at reactivation of
LATS kinase activity.
YAP/TAZ and mechanotransduction
In addition to the inhibitory module provided by the
Hippo kinases, YAP/TAZ have been more recently dis-
covered as central mediators of cellular mechanotransduc-
tion. Cells are in fact constantly targeted by mechanical
forces from their attachment to their surrounding extra-
cellular matrix (ECM) or to other cells, and this molds cell
shape and cytoskeletal organization [12–14]. Patterns of
mechanical forces are intrinsic to the 3D architecture and
geometry of our tissues, and represent dominant modali-
ties to regulate cell fate.
Mechanical signals represent an overarching determinant
in the control of YAP/TAZ activity [15,16]; differently from
the Hippo pathway, cell mechanics represent a positive
and permissive modality to activate YAP/TAZ, offering
unanticipated routes for therapeutic interventions. YAP
and TAZ are activated by ECM stiffness, by stretched cell
shape, and by an F-actin organization typified (at least in
vitro) by stress-fibers and elevated cytoskeletal tension
(reviewed in [12]); in contrast YAP/TAZ are inhibited
by soft ECM environments, by round cell shape, and by
cell physical confinement within a restricted space. YAP/
TAZ activation by cell mechanics is influenced by Rho-
GTPase, ROCK and integrity of the actomyosin cytoskel-
eton, in a manner largely independent from LATS
[15–17]. Mechanotransduction affects YAP/TAZ activity
in all cells, irrespectively of their load of oncogenic muta-
tions; for example, a soft ECM is effective at restricting
YAP/TAZ in normal, benign and metastatic cancer cells.
In most adult epithelial organs, YAP/TAZ levels and
activity are barely detectable or confined to specific tissue
niches. This is consistent with the view that most cells in
living tissues rest in a ‘soft’ mechanical condition,
experiencing low mechanical forces incompatible with
YAP/TAZ activation and cell proliferation, and consistent
with the notion that the structural and physical features of
our tissues are intrinsically tumor suppressive [18,19].
This scenario changes dramatically during tumor progres-
sion, whereby disturbed tissue architecture, accumulation
of stromal cells, increased compression forces, ECM
stiffening with changes in ECM composition and activa-
tion of cancer-associated fibroblasts (CAFs) all represent
conditions potentially able to induce stable YAP/TAZ
activation in a large fraction of cancer cells.
YAP/TAZ mechanotransduction may be also active in the
cells of the tumor microenvironment. For example, YAP
is activated in CAFs, by mechanisms involving Src and
ROCK [20]. YAP activation in CAFs leads to ECMwww.sciencedirect.com stiffening and thus generates a mechanically activated
feedback loop that promotes increased extracellular
matrix protein deposition, tissue rigidity, and YAP/
TAZ-driven aberrant proliferation in tumor cells.
The mechanism(s) linking mechanically-activated cyto-
skeletal changes to YAP/TAZ are largely unknown; yet,
the identification of YAP/TAZ as downstream effectors of
cellular mechanotransduction bears several implications
for cancer biology and its possible treatment.
Role of YAP/TAZ in installing drug resistance
and escaping oncogene addiction
A key property of CSCs, and indeed of tumor cells with
activated YAP/TAZ, is resistance to chemotherapeutic
drugs. YAP/TAZ activation sustains survival of breast
cancer stem cells treated with conventional chemother-
apeutics, such as paclitaxel and doxorubicin, and protects
cancer cells against DNA-damaging agents, including
cisplatin and radiations. [1,8,9].
Furthermore, YAP/TAZ promote resistance to molecu-
larly targeted therapies in tumor cells harboring specific
oncogenic lesions. Lin and colleagues reported that YAP
promotes resistance to RAF and MEK inhibitors in sev-
eral tumor cell lines harboring BRAF, KRAS or NRAS
activating mutations [21]. As such, YAP downregulation
enhanced the efficacy of RAF and MEK inhibitors in
mutant cells that had acquired resistance to these drugs.
Immunohistochemistry (IHC) analysis in human melano-
ma specimens bearing BRAF mutations revealed a ten-
dency for primary tumors with high YAP expression to
display an incomplete response or no response to therapy
with RAF/MEK inhibitors. Thus, YAP acts as a parallel
survival input for tumor cells and its upregulation dam-
pens the efficacy of oncogene-specific, molecularly tar-
geted agents.
YAP mechanotransduction pathway has been recently im-
plicated in the acquisition of drug resistance in melanoma
and breast cancer. In melanoma, resistance to the BRAF-
inhibitor vemurafenib is paralleled by cell stretching, in-
creased content of actin stress fibers and mechano-depen-
dent YAP activation [22]. Consistently, the responsiveness
of HER2-positive breast cancer cells to lapatinib is en-
hanced on soft matrices, and blunted in stiff matrices in a
YAP/TAZ-dependent manner [23]. Of note, in vivo studies
have demonstrated that BRAF inhibitors do not only act in
melanoma cells but also in the surrounding tumor fibro-
blasts, in fact activating them to produce a stiff, collagen-
rich extracellular matrix (ECM) [24]. An intriguing hypoth-
esis is that these two events — the cell-autonomous in-
crease in responsiveness to ECM rigidity, and the stiffening
of surrounding ECM — might occur simultaneously and
concur to the activation of YAP in therapy-resistant cancer
cells [25]. It is thus plausible that attenuation of YAP/TAZ-
dependent mechanotransduction through inhibitors ofCurrent Opinion in Pharmacology 2016, 29:26–33
28 Cancerintegrin signaling or cytoskeletal modulators — including
drugs targeting FAK, Src family members, Rho-GTPases or
ROCK (see below) — may represent an intriguing avenue
to blunt cancer chemoresistance.
Just like YAP/TAZ activation can bypass drug resistance,
it can also bypass oncogene addiction. For example,
pancreas-specific expression of KRASG12D from an induc-
ible transgene leads to the development of pancreatic
ductal adenocarcinomas (PDAC) in mice, but tumors
regress and disappear when the transgene is experimen-
tally turned off. Yet, some tumors spontaneously relapse
in the absence of any KRASG12D overexpression through
amplification of the YAP1 locus, as such providing genetic
evidence that YAP-overexpressing cellular clones are
positively selected upon KRAS-inactivation [26]. In line
with this notion, the relapsed tumor cells require YAP/
TAZ to sustain tumor growth. In other words, as tumor
cells gain independency from their initiating oncogenic
lesions by activating YAP/TAZ, they also gain a higher
dependency on YAP/TAZ themselves. This opens inter-
esting therapeutic scenarios for synthetic lethal
approaches, whereby attenuation of YAP/TAZ activity
in combination with drugs targeting cancer-relevantFigure 1
Gα inhibitors
Tankyrase
inhibitors
Hippo
kinases
WNT
ligands
F
APC/Axin
Energy
stress
YAP
TAZ
GPCR
Summary of positive and negative regulators of YAP/TAZ. Drugs of potentia
detailed representation of molecular pathways regulating F-actin and mecha
Current Opinion in Pharmacology 2016, 29:26–33 mutations may effectively kill tumor cells, avoid relapse
and, at the same time, spare normal cells.
Routes for anti-YAP/TAZ therapeutic
interventions
YAP/TAZ are at the nexus of several signaling cascades
(Figure 1), in turn suggesting a number of potential
therapeutic options.
Targeting mechanotransduction
The actin cytoskeleton offers a potentially rich and still
largely unexplored set of opportunities to control YAP/
TAZ activity [12]. The polymerization, organization and
tensile states of cellular F-actin rely on the activity of
Rho, Rac and CDC42 GTPases. ROCK kinases are
downstream of Rho, and control F-actin polymerization
by regulating LIMKs (LIMK1/2), that are also down-
stream of Rac/PAK signaling. LIMKs are inhibitors of
Cofilin/ADF, proteins involved in F-actin capping and
severing that ultimately promote F-actin depolymeriza-
tion (Figure 2). Capping and severing proteins have been
recently shown to serve as potent regulators of YAP/TAZ
activity: loss-of-Cofilin/CapZ/Gelsolin can overcome
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indicated.a manner independent from LATS kinase activity [15,27].
Intriguingly, conditional inactivation of Cofilin and its
related protein ADF in mouse models triggers dramatic
organ overgrowths [28]. Consistently, ROCK and PAK
have been already reported to sustain YAP/TAZ function
[16,20]; some cell types appear however insensitive to
ROCK inhibition [29], possibly because of redundant
function with MLCK. Cofilin/ADF are opposed by anti-
capping factors, such as ENA/Vasp and by ARP2/3.
The above outline indicates several routes to blunt YAP/
TAZ activity by targeting mechanotransduction, at least
in vitro (Figure 2). These include direct disruption of F-
actin microfilaments, or inhibition of upstream activators
of F-actin [16]. However, toxicity of anti-cytoskeletal
treatments makes most of them unlikely to be translated
in the clinical practice. Therapeutic options are currently
limited to inhibitors of Rho and its upstream inducers,
such as Src, FAK and integrins. For example, the SRC-
family inhibitor dasatinib (already in clinical practice for
treatment of leukemias) has been recently shown to
oppose YAP/TAZ transcriptional effects in vitro and in
vivo [20,30].
YAP/TAZ regulation by the cytoskeleton is a broadly
general phenomenon allowing integration with otherwww.sciencedirect.com pathways known to indirectly control F-actin stability
and organization. A point in case is the mevalonate path-
way. This metabolic cascade generates geranylgeranyl
moieties essential for the post-translational modification
and membrane localization of Rho-GTPases. The key
enzyme of this cascade, HMG-CoA reductase, is inhibited
by statins, a class of drugs widely used to treat hypercho-
lesterolemia. Indeed, statins caused YAP/TAZ inhibition
and cytoplasmic relocalization in several cancer cell types;
moreover, TAZ-dependent preservation of cancer stem
cells in vitro and their growth as tumor xenografts in vivo
were reduced upon statin treatment [17,31,32].
The anti-YAP/TAZ effect of statin appeared stronger in
vitro than in vivo, suggesting that it may be difficult to keep
statin concentration above the minimal threshold of effec-
tiveness within tumors. Statins are however significantly
more potent at inhibiting YAP/TAZ activity when com-
bined with Src inhibitors [33]. It is suggestive that, in
epidemiological studies, statin-taking patients display re-
duced risk to develop cancer [34]. In addition to statins,
bisphosphonates (FDA approved drugs) and GGTI (inhi-
bitors of geranylgeranyl transferase-1) represent additional
compounds targeting the mevalonate pathway that
are relevant for Rho-GTPase signaling, and that display
YAP/TAZ inhibiting abilities (Figure 1) [17,35].Current Opinion in Pharmacology 2016, 29:26–33
30 CancerTargeting the energy metabolism
Differently from normal differentiated cells, which rely
primarily on mitochondrial function to generate ATP, most
cancer cells rely on aerobic glycolysis. This so-called ‘War-
burg effect’ impacts on YAP/TAZ regulation likely by
distinct mechanisms. For example, inhibition of glycolysis
with 2-deoxy-D-glucose blunted YAP/TAZ transcriptional
activity and transforming capacity in vitro [36–38]. Alterna-
tively, AMPK, a kinase that senses cellular ATP levels, also
partially inhibits YAP/TAZ. AMPK activation by AICAR or
metformin (AMPK agonists used in diabetic patients) down-
regulates expression of YAP/TAZ target genes [37,39] and
reduces the outgrowth of transplanted LATS1/2 double
knockout MEFs [37]. Envisioning a pro-AMPK approach
to hit YAP/TAZ in tumor cells is however unlikely, given
that, at odd with its proposed anti-YAP/TAZ effects, AMPK
is itself a tumor promoter fostering cancer cell survival [40].
Targeting GPRC signaling
Signaling from G-protein-coupled-receptors (GPCR) and
their ligands has been recently shown to regulate YAP/
TAZ activity, once again involving a central role for Rho
and the actin cytoskeleton. GPCRs represent a large
family of receptors; depending on the specific subset of
G-proteins involved, this regulation can be inhibitory or
activating: Ga12/13-, Ga11-, Ga1/o-coupled receptors
induce YAP/TAZ, whereas Gas-coupled receptors op-
pose them [41]. Consistently with their role as Rho
inducers, GPCRs require a sufficient ‘mechanical tone’
in the target cells in order to sustain YAP/TAZ activity, as
GPCR ligands are unable to overcome YAP/TAZ me-
chanical inhibition in cells plated in soft ECMs [15]. In
addition, Gas-coupled GPCRs raise PKA/cAMP levels,
leading to activation of Hippo/LATS signaling [41].
GPCRs are also a prominent family of validated pharma-
cological targets suggesting that their selective inhibition
may represent a way to blunt YAP/TAZ activity, particu-
larly in tumors driven by mutations in the GPCR pathways.
A paradigm for this scenario is the frequent mutation of
Gaq and Ga11 in uveal melanoma [42,43]. Overexpression
of oncogenic Gaq in melanocytes activates YAP and
induces melanoma formation. Clearly, GPRCs can activate
other pathways whose biological effect may or not be
coherent with their YAP/TAZ regulation. In fact, appar-
ently at odd with their anti-YAP/TAZ effects, Gas-coupled
GPRCs are activated by mutations in some tumor types
[44], and their inhibition by b-blockers has been proposed
as anti-cancer treatment [45]. It is plausible that other, pro-
tumorigenic Gas-GPCR downstream responses may over-
rule YAP/TAZ activation in these contexts.
Turning off Wnt/YAP-TAZ signaling by sustaining the
activity of the destruction complex using Tankyrase
inhibitors
Recent studies found that cytoplasmic YAP/TAZ associate
to the destruction complex, involved in the degradationCurrent Opinion in Pharmacology 2016, 29:26–33 and sequestration of b-catenin and other proteins [5]. YAP/
TAZ bind directly to Axin, APC and b-catenin [5,46,47],
and this contributes to their cytoplasmic sequestration and
to TAZ degradation [5,48]. Mutation or experimental
depletion of Axin1/2 or APC, or Wnt stimulation, all inhibit
the destruction complex, fostering YAP/TAZ nuclear ac-
cumulation and target genes transcription [5,48,49]. Con-
sistently, conditional knockout of APC in the intestinal
epithelium leads to massive YAP/TAZ nuclear stabiliza-
tion. Strikingly, crypt overgrowth and intestinal adenoma
formation downstream of APC inactivation depends on
YAP/TAZ [5,46,50]. YAP/TAZ activation by the Wnt
pathway can be prevented by reactivation of the destruc-
tion complex by treatment with tankyrase inhibitors [48],
that is, compounds that promote Axin stabilization. Inter-
estingly, these compounds can restore the activity of the
destruction complex also in colorectal cancer (CRC) cells
bearing truncations of APC [51], suggesting that these
compounds may have a dual anti-b-catenin and anti-
YAP/TAZ activity that might be exploited in CRC
patients.
Targeting YAP/TAZ transcriptional
mechanisms
The mechanisms by which nuclear YAP/TAZ control
gene expression represent a largely unexplored but po-
tentially promising area to design new modalities of
therapeutic interventions. Since all upstream regulators
ultimately impact on YAP/TAZ nuclear availability and
transcriptional responses, designing compounds able to
interfere at these levels may represent an ‘universal’ anti-
YAP/TAZ approach; this approach may also display the
added advantage of reduced toxicity compared to drug-
ging upstream signaling molecules likely endowed with
pleiotropic functions.
YAP/TAZ are transcriptional co-activators that do not
bind DNA directly [2]. Only very recently, ChIP-seq
and transcriptomic experiments provided the first global
picture of the nuclear partners of YAP/TAZ in several
cancer cell lines [52,53,54]. This work collectively indi-
cates that TEAD is by far the primary DNA binding
platform for YAP/TAZ.
The structure of the YAP-TEAD binding domains has
been resolved, indicating extensive interactions through
evolutionary conserved interfaces [55,56]. However, it
remains undetermined whether this interaction could
be exploited for rational design of small ligands. Verte-
porfin (VP — belonging to the porphyrin family), the only
compound able to inhibit the physical association be-
tween YAP and TEAD [57], actually emerged from an
unbiased functional screen of FDA-approved drugs able
to blunt YAP/TAZ activity, and not from rational design.
In transgenic mice, VP appears to limit liver overgrowth
resulting from either YAP overexpression or activation of
endogenous YAP by Nf2 knockout [57]. VP has beenwww.sciencedirect.com
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melanoma cells in an orthotopic mouse model [43], and of
pre-established xenografts of prostate cancer cells bearing
activated YAP [58]. That said, a recent study reports that
VP suppresses the proliferation of cancer cells by induc-
ing toxicity, acting irrespectively of YAP [59].
The potential validity of an anti-YAP/TEAD strategy is
corroborated by evidence that a short peptide competing
with YAP for the binding to TEAD, could inhibit YAP-
dependent tumorigenic potential of gastric cancer cells
both in vitro and in vivo [60]. This peptide was designed
on the sequence of VGLL4, a protein that interacts with
TEAD, in a way that is mutually exclusive with YAP
[60,61]. In spite of the mild therapeutic efficacy shown by
the VGLL4-mimicking peptide, the results obtained with
this approach are encouraging, and strengthen the view
that the YAP/TAZ-TEAD interface is a promising drug
target.
How do YAP/TAZ control the expression of target genes?
YAP/TAZ bind to enhancers that are ‘in touch’ with their
cognate promoters through chromatin loops [52]; in these
structures, YAP/TAZ would promote elongation of na-
scent mRNA molecules by recruiting the Mediator com-
plex [53], a multi-subunit complex that communicate
regulatory signals from DNA-bound TFs directly to
the basic transcriptional machinery. Indeed, YAP/TAZ
depletion impairs recruitment of the Mediator complex,
and diminishes PolII levels on gene bodies [53]. An
encouraging result was obtained with flavonoids, com-
pounds able to oppose CDK9, a subunit of the positive
transcription elongation factor, P-TEFb, which promotes
mRNA elongation. These treatments could at least par-
tially limit the rapid liver overgrowth induced by trans-
genic YAP overexpression in mice [53]. YAP/TAZ also
promote acetylation of histones located in enhancers,
raising the prospect that small molecule inhibitors of
histone acetyltransferases may limit YAP/TAZ [52,54].
An unexpected discovery that emerged from YAP/TAZ/
TEAD ChIP-seq explorations has been the elucidation
that these factors do not work in isolation: in order to turn
on their oncogenic growth program, YAP/TAZ must
cooperate with AP-1 (Activator Protein 1) dimers
[52,54,62]. YAP/TAZ, TEAD and AP-1 form a transcrip-
tion factor complex, and synergistically activate target
genes to promote cell transformation. Notably, the AP1-
YAP/TAZ/TEAD cooperation is extensive, occurring in
the majority of YAP/TAZ-bound chromatin sites. It is
thus plausible that AP-1 inhibitors, such a retinoids, may
be effective at limiting the pro-oncogenic properties of
YAP/TAZ.
YAP has been recently proposed to serve as tumor sup-
pressor in hematological malignancies [63]. Consistently,
a pro-apoptotic role of YAP has also been reported, at leastwww.sciencedirect.com in some contexts [64]. The models proposed entail func-
tional cooperation between YAP and p53 family members
for activation of pro-apoptotic target genes [64]. Mutation
of p53 induces neomorphic or ‘gain-of-function’ proper-
ties and, intriguingly, YAP has been shown to contribute
to the pro-proliferative effects of mutant-p53 proteins
[17,65].
Considering these insights, we speculate that a deeper
understanding of the molecular mechanisms of YAP/TAZ
nuclear function might offer further opportunities to
target their oncogenic functions.
Conclusions
The prominence of YAP/TAZ for many aspects of cancer
biology indicates these factors as ideal targets for devel-
opment of anticancer treatments. From the above discus-
sion, inhibition of YAP/TAZ remains challenging, as
many protein-protein interactions specifically involved
in the control of YAP/TAZ activity may be difficult to
target. Several enzymes operating in pathways that acti-
vate YAP/TAZ, such as in mechanotransduction, do war-
rant further investigation, although their targeting with
small molecules may be associated to toxicity.
The nuclear mechanisms underlying YAP/TAZ-mediat-
ed transcription may represent so far underestimated
opportunities of intervention. For example, YAP/TAZ
control cancer cell fates, hinting to their involvement
as epigenetic modifiers; although presently unknown,
dissecting these regulatory layers may link YAP/TAZ
inhibition to an arsenal of potent epigenetic drugs. Also
underdeveloped is the possibility to target YAP/TAZ-
downstream effectors. We and others have recently iden-
tified a host of YAP/TAZ direct target genes involved in
the control of cell cycle progression. In addition, YAP/
TAZ induce receptors and secreted ligands that are
traditionally ideal targets for biologic drugs. More specu-
latively, how YAP/TAZ mRNA levels are regulated has
been almost entirely neglected, including the existence
of post-transcriptional regulations by miRNAs or ceRNAs
that are also appealing targets for innovative drugs. Fi-
nally, the ability of YAP/TAZ to reprogram cancer cells
and to operate from complex enhancers indicate that
these factors must act combinatorially as segments of a
stemness network operating in somatic cells, whose other
components remain to be discovered. Clearly, more re-
search in this field is likely to disclose so far unexpected
and potentially very effective anti-YAP/TAZ pharmaco-
logical strategies for cancer treatment.
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